CMS-D003 is a cardiac myosin inhibitor classified as a targeted therapy for the treatment of hypertrophic cardiomyopathy, including the obstructive form of the disease. By inhibiting cardiac myosin adenosine… Read more
CMS-D003 is a cardiac myosin inhibitor classified as a targeted therapy for the treatment of hypertrophic cardiomyopathy, including the obstructive form of the disease. By inhibiting cardiac myosin adenosine triphosphate enzymes, this compound works to reduce myocardial hypercontractility and improve diastolic function. Within this category, researchers and pharmaceutical laboratories access the parent drug alongside stable isotope labelled compounds to support critical analytical workflows. These reference standards are essential tools for method validation, quantitative analysis, and quality control, particularly in high-sensitivity procedures like liquid chromatography-mass spectrometry (LC-MS/MS). By utilizing these high-purity materials, laboratories can ensure accurate impurity profiling, precise drug quantification, and rigorous assessment of drug behaviour, facilitating both early-stage research and the development of therapeutic formulations.